Key Stats for LeMaitre Vascular Stock
- Past-Week Performance: +16.4%
- 52-Week Range: $71.4 to $115.3
- Current Price: $106.4
What Happened?
LeMaitre Vascular‘s decision to triple its Artegraft total addressable market estimate to $30 million on February 25 reframes the company from a legacy vascular tools operator into a biologics-driven compounder, with shares now trading at $106.41.
That same earnings call delivered a Q4 sales beat of $64.5 million against a $62.8 million consensus, while management simultaneously authorized a $100 million share repurchase program and raised the quarterly dividend 25% to $0.25 per share.
Beneath the headline beat, Q4 operating income surged 47% to $18.8 million as gross margin expanded 240 basis points to 71.7%, powered by an 8.3% blended price hike that hospital customers accepted without friction starting January 1.
Adding to the growth narrative, OUS Artegraft revenue hit $4 million for full-year 2025, doubling management’s original $2 million expectation, with 2026 guidance targeting $10 million as the launch accelerates across Southern and Northern Europe.
Chairman and CEO George LeMaitre stated on the Q4 earnings call that “2025 was another year of operating leverage at LeMaitre, sales were up 14% and op income was up 30,” as the company heads into five March investor conferences spanning Leerink Partners on March 10 through ROTH on March 22.
Looking further out, LeMaitre’s combination of direct-country expansion into a 32nd market in Poland, a $359 million cash position, and an active acquisition pipeline targeting 22 open vascular and cardiac surgery candidates positions the company to compound well beyond its 12% organic growth guidance for 2026.
Wall Street’s Take on LMAT Stock
That Q4 earnings beat directly strengthens LeMaitre’s forward revenue trajectory, with management guiding 12% organic sales growth and 21% adjusted operating income growth for full-year 2026.
The fundamental case is equally compelling: EPS is forecast to grow 14.5% to $2.89 in 2026, while EBITDA margins are projected to expand to 31.8% from 29.8% in 2025.
As of March 5, 9 of 9 covering analysts hold a buy or outperform rating, with zero sells, and a mean price target of $109.22 implying roughly 2.6% upside from the current $106.41 close.
The target range spans $94.00 on the low end to $124.00 on the high end, with the bull case anchored to continued Artegraft OUS momentum and the bear case reflecting execution risk from the Chicago-to-Burlington manufacturing transfer.
What Does the Valuation Model Say?
The TIKR valuation model prices LMAT at $151.00 under mid-case assumptions, suggesting the stock trades roughly 42% below its intrinsic value through December 2030.
The market appears to be underpricing LeMaitre’s biologics inflection, despite management tripling its Artegraft TAM estimate to $30 million on the February 25 earnings call.
A company generating $74.5 million in free cash flow while trading at 35x forward earnings rarely carries a 15-consecutive-year dividend growth streak alongside a fresh $100 million buyback authorization.
That combination of capital return discipline and accelerating biologics revenue suggests the Street’s 2.6% mean upside estimate materially understates the compounding potential already embedded in the 2026 guidance.
Execution risk on the RestoreFlow manufacturing transfer from Chicago to Burlington represents the clearest near-term threat to the 72.1% gross margin guide.
The March investor conference circuit, spanning five events including Barclays on March 12 and ROTH on March 22, will reveal whether institutional buyers step in to close the gap between the $106.41 price and the $151.00 model target.
LMAT is a high-conviction compounder with a biologics growth engine the market has not yet fully priced, and the March conference cycle is the next test of that thesis.
Should You Invest in LeMaitre Vascular, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up LMAT stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track LeMaitre Vascular, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze LMAT stock on TIKR for Free →
